Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2641 to 2655 of 8911 results

  1. Camizestrant as an add-on to palbociclib and abemaciclib for untreated hormone receptor-positive HER2-negative metastatic breast cancer with an ESR1 mutation [ID6535]

    Awaiting development Reference number: GID-TA11687 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Tislelizumab with platinum-based chemotherapy and etoposide for untreated extensive-stage small-cell lung cancer [ID6158]

    Awaiting development Reference number: GID-TA11094 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Apraglutide for treating short bowel syndrome [ID6533]

    Awaiting development Reference number: GID-TA11695 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Trastuzumab deruxtecan for treating HER2-positive advanced gastric or gastro-oesophageal junction adenocarcinoma after trastuzumab-based treatment (review of TA879) [ID6680]

    In development Reference number: GID-TA11963 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Anitocabtagene autoleucel for treating relapsed or refractory multiple myeloma [ID6549]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  6. Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome (review of HST31) [ID6598]

    In development Reference number: GID-HST10067 Expected publication date:  19 August 2026

    Highly specialised technologies guidance
    In development

  7. Radium-223 dichloride with enzalutamide for treating asymptomatic or mildly symptomatic hormone-relapsed metastatic prostate cancer with bone metastases [ID6512]

    Awaiting development Reference number: GID-TA11657 Expected publication date:  07 April 2027

    Technology appraisal guidance
    Awaiting development

  8. Belzutifan with lenvatinib for treating advanced renal cell carcinoma after a PD-1 or PD-L1 inhibitor [ID6476]

    Awaiting development Reference number: GID-TA11584 Expected publication date:  08 December 2027

    Technology appraisal guidance
    Awaiting development

  9. Dersimelagon for treating erythropoietic protoporphyria and X-linked protoporphyria in people 12 years and over [ID6160]

    Awaiting development Reference number: GID-TA11085 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Vimseltinib for treating tenosynovial giant cell tumours when surgery is unsuitable [ID6736]

    Awaiting development Reference number: GID-TA11964 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Nivolumab with BMS-986205 and chemotherapy for neoadjuvant treatment of muscle-invasive bladder cancer [ID6321]

    Awaiting development Reference number: GID-TA11336 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Capsule sponge tests for detection of Barrett's oesophagus and early-stage oesophageal cancer and surveillance of Barrett's oesophagus [ID6683]

    In development Reference number: GID-TA11960 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Chronic anal fissure: 2% topical diltiazem hydrochloride (ESUOM3)

    Summary of the evidence on 2% topical diltiazem hydrochloride for chronic anal fissure to inform local NHS planning and decision-making

    Evidence summary
    Published
    22 January 2013

  14. Bile acid malabsorption: colesevelam (ESUOM22)

    Summary of the evidence on colesevelam for treating bile acid malabsorption (BAM) to inform local NHS planning and decision-making

    Evidence summary
    Published
    29 October 2013

  15. Ovarian cancer (advanced): bevacizumab 7.5 mg/kg in combination with paclitaxel and carboplatin for first-line treatment (ESUOM21)

    Summary of the evidence on bevacizumab 7.5 mg/kg with paclitaxel and carboplatin for the first-line treatment of advanced ovarian cancer..

    Evidence summary
    Published
    22 October 2013